Table 3

Analysis of subgroups

SubgroupSAEDAEExacerbations (any category)
FormSalbFormSalbFormSalbHazard ratio Form/Salb (95% CI)
Age groups
 Children19 (2.3)14 (1.7)5 (0.6)1 (0.1)32.435.00.904 (0.766–1.067)
 Adolescents16 (2.0)16 (2.0)14 (1.8)6 (0.8)23.626.10.892 (0.731–1.087)
 Adults182 (2.8)205 (3.2)151 (2.4)87 (1.4)29.133.10.857# (0.806–0.912)
 Elderly61 (6.8)64 (6.9)43 (4.8)25 (2.7)25.230.00.815# (0.684–0.972)
Severity judged by asthma medication levels
 Intermittent25 (1.8)18 (1.3)30 (2.2)14 (1.0)24.925.70.971 (0.837–1.126)
 Mild91 (2.9)77 (2.5)59 (1.9)34 (1.1)27.331.10.854# (0.779–0.937)
 Moderate92 (3.0)108 (3.5)69 (2.2)50 (1.6)28.132.10.853# (0.779–0.934)
 Severe70 (5.3)96 (7.1)55 (4.2)21 (1.5)36.742.60.824# (0.730–0.930)
Maintenance medication type
 LABA111 (4.0)145 (5.0)75 (2.7)43 (1.5)32.335.50.891# (0.815–0.975)
 No LABA167 (2.7)154 (2.5)138 (2.2)76 (1.3)26.930.90.849# (0.795–0.907)
 ICS229 (3.4)257 (3.8)172 (2.5)93 (1.4)29.533.80.850# (0.801–0.903)
 No ICS49 (2.3)42 (2.0)41 (1.9)26 (1.2)25.627.80.906 (0.806–1.017)
  • Data are presented as n (%) unless otherwise stated

  • SAE: serious adverse events

  • DAE: discontinuations due to adverse events

  • Form: Formoterol

  • Salb: Salbutamol

  • 95% CI: 95% confidence interval

  • LABA: long-acting β2‐agonist

  • ICS: inhaled corticosteroids

  • #: significant treatment difference

  • :Defined in accordance to Global Initiative for Asthma guidelines as a surrogate for asthma severity (see table 1 footnote for definitions and subgroup sizes)